EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide

Hong Sheng Cheng iD, Yuk Kien Chong, Eldeen Kai Yi Lim, Xin Yi Lee, Qing You Pang, Wisna Novera, Charlie Marvalim, Jeannie Xue Ting Lee, Beng Ti Ang, Carol Tang, Nguan Soon Tan

Neuro-Oncology · 05.07.2024 · 26 (7) · 1247-1261

DOI: 10.1093/neuonc/noae028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 16.02.2024. Verfasst von Hong Sheng Cheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Drug Resistance, Neoplasm, p38 Mitogen-Activated Protein Kinases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health's National Medical Research Council, BenevolentAI, Ministry of Health’s National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Precision treatment of glioblastoma is increasingly focused on molecular subtyping, with the mesenchymal subtype particularly resistant to temozolomide. Here, we aim to develop a targeted therapy for temozolomide resensitization in the mesenchymal subtype.

Methods

We integrated kinomic profiles and kinase inhibitor screens from patient-derived proneural and mesenchymal glioma-propagating cells and public clinical datasets to identify key protein kinases implicated in temozolomide resistance. RNAseq, apoptosis assays, and comet assays were used to examine the role of p38MAPK signaling and adaptive chemoresistance in mesenchymal cells. The efficacy of dual p38MAPK and MEK/ERK inhibition using ralimetinib (selective orally active p38MAPK inhibitor; phase I/II for glioblastoma) and binimetinib (approved MEK1/2 inhibitor for melanoma; phase II for high-grade glioma) in primary and recurrent mesenchymal tumors was evaluated using an intracranial patient-derived tumor xenograft model, focusing on survival analysis.

Results

Our transcriptomic-kinomic integrative analysis revealed p38MAPK as the prime target whose gene signature enables patient stratification based on their molecular subtypes and provides prognostic value. Repurposed p38MAPK inhibitors synergize favorably with temozolomide to promote intracellular retention of temozolomide and exacerbate DNA damage. Mesenchymal cells exhibit adaptive chemoresistance to p38MAPK inhibition through a pH-/calcium-mediated MEK/ERK pathway. Dual p38MAPK and MEK inhibition effectively maintain temozolomide sensitivity in primary and recurrent intracranial mesenchymal glioblastoma xenografts.

Conclusions

Temozolomide resistance in mesenchymal glioblastoma is associated with p38MAPK activation. Adaptive chemoresistance in p38MAPK-resistant cells is mediated by MEK/ERK signaling. Adjuvant therapy with dual p38MAPK and MEK inhibition prolongs temozolomide sensitivity, which can be developed into a precision therapy for the mesenchymal subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaDrug Resistance, Neoplasmp38 Mitogen-Activated Protein KinasesBrain NeoplasmsXenograft Model Antitumor AssaysHumansAnimalsMiceAntineoplastic Agents, AlkylatingProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesTumor Cells, CulturedCell ProliferationApoptosisPrognosis

Stichwörter der Autor:innen

MAPK signalingbrain cancergliomaprecision medicinetargeted therapy

Substanzen

Temozolomidep38 Mitogen-Activated Protein KinasesAntineoplastic Agents, AlkylatingProtein Kinase InhibitorsMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore.
  • School of Biological Sciences, Nanyang Technological University Singapore, Singapore, Singapore.
  • Neuro-Oncology Research Laboratory, Department of Research, National Neuroscience Institute, Singapore, Singapore.
  • Department of Neurosurgery, National Neuroscience Institute, Singapore, Singapore.
  • Duke-National University of Singapore Medical School, Singapore, Singapore.

ORCID-Profile: Hong Sheng Cheng

Förderung

  • Ministry of Health's National Medical Research Council
  • BenevolentAI
  • Ministry of Health’s National Medical Research Council

Zitieren

APA

Cheng, H. S., Chong, Y. K., Lim, E. K. Y., Lee, X. Y., Pang, Q. Y., Novera, W., Marvalim, C., Lee, J. X. T., Ang, B. T., Tang, C., & Tan, N. S. (2024). Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide. Neuro-Oncology, 26(7), 1247-1261. https://doi.org/10.1093/neuonc/noae028

Vancouver

Cheng HS, Chong YK, Lim EKY, Lee XY, Pang QY, Novera W, et al. Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide. Neuro-Oncology. 2024;26(7):1247-1261. doi:10.1093/neuonc/noae028

BibTeX
@article{Cheng2024,
  author = {Cheng, Hong Sheng and Chong, Yuk Kien and Lim, Eldeen Kai Yi and Lee, Xin Yi and Pang, Qing You and Novera, Wisna and Marvalim, Charlie and Lee, Jeannie Xue Ting and Ang, Beng Ti and Tang, Carol and Tan, Nguan Soon},
  title = {Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {7},
  pages = {1247--1261},
  doi = {10.1093/neuonc/noae028}
}
Kostenlos starten →